Like many of the factors discussed above, there are no known direct NEUROD1-targeting therapies; however, targeting its coactivator, BET, bromodomain proteins by BET inhibitors (JQ-1) has demonstrated efficacy in SCLC [117], suppressing NEUROD1 signalling and inhibiting growth in vitro. This evidence concerns the gene NEUROD1 and small cell lung carcinoma.